You are here: Industry Insights > TSC

News List

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation firstwordpharma
August 18, 2021
Marinus Pharmaceuticals, Inc. today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).
MHRA approves for Epidyolex® (cannabidiol) for TSC seizure treatment europeanpharmaceuticalreview
August 13, 2021
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
UK approval for Epidyolex to treat seizures from tuberous sclerosis pharmatimes
August 11, 2021
Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis ...
Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis firstwordpharma
May 27, 2021
via NewMediaWire today announced that it is completing patient enrollment in the Phase 2b CONTROL study evaluating TMB-001, a topical pharmaceutical composition of isotretinoin
GW Pharma’s Epidyolex scores new EU indication pharmatimes
April 22, 2021
GW Pharmaceuticals’ Epidyolex has received approval from the European Commission (EC) for the treatment of seizures associated with tuberous sclerosis complex (TSC) – its third indication in Europe.
GW Pharmaceuticals Receives European Commission Approval for EPIDYOLEX® (cannabidiol) for the Treatment of Seizures Associated with Tuberous Sclerosis Complex americanpharmaceuticalreview
April 21, 2021
GW Pharmaceuticals plc, a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® ...
GW Receives Positive CHMP Opinion for EPIDYOLEX for TSC Seizures americanpharmaceuticalreview
March 04, 2021
GW Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive ...
FDA Approves New Indication for Drug Containing Cannabis for Seizures in Rare Genetic Disease americanpharmaceuticalreview
August 10, 2020
The U.S. Food and Drug Administration (FDA) has approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.
FDA approves Epidyolex for treatment of tuberous sclerosis complex-associated seizures europeanpharmaceuticalreview
August 04, 2020
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
Purified CBD May Help Treat Drug-Resistant Epilepsy drugs
December 26, 2019
Among patients with tuberous sclerosis complex (TSC), the reduction in the frequency of TSC-associated seizures was greater in those receiving a purified version of cannabidiol (CBD) than ...

Previous page 1 2 Next page